Last update:

Clinical pharmacology news

New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks

A new strategy for delivering GLP-1 drugs to patients with obesity or who were overweight resulted in up to a 12% reduction in body weight after 36 weeks, according to a randomized phase II clinical trial published in Nature ...

How high cholesterol dismantles the liver's defenses—and how a new drug could combat it

Cholesterol-related heart disease remains the leading cause of death worldwide, and while doctors have more tools than ever to treat it, many patients still can't achieve safe cholesterol levels or can't tolerate the side ...

FDA approves another over-the-counter naloxone nasal spray

The U.S. Food and Drug Administration has approved another over-the-counter intranasal naloxone product, Rextovy (naloxone hydrochloride), for the emergency treatment of opioid overdose. The nonprescription approval was granted ...

Engineered probiotic heads to human trials

A probiotic bioengineered by UBC Okanagan researchers to thrive in the inflamed gut is set to enter human clinical trials in Australia this summer, capping a decade-long effort to turn a beneficial bacterium into a treatment ...